Industry Eyes DPP-4, GLP-1 Data From Diabetes Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
BMS to release first Phase III data on saxagliptin as monotherapy.
You may also be interested in...
Takeda’s Alogliptin Strategy: Treatment Options
With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.
Takeda’s Alogliptin Strategy: Treatment Options
With five Phase III wins for type 2 diabetes, company plans to build on Actos’ success.
Liraglutide Up For Approval In U.S. And Europe
Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.